Physicians significantly underestimated the proportion of patients with systemic sclerosis who experienced pain, with rates of 43.4% vs 96.0%.

In the second quarter of 2025, Zura Bio initiated TibuSHIELD, a global Phase 2 clinical study evaluating tibulizumab in adults with moderate to severe HS. A topline data readout is anticipated in the ...

Both systemic sclerosis and systemic lupus erythematosus have down-regulated RGS5, but they also have distinctive genetic ...

A 28-year-old woman was admitted to the hospital because of severe hypoxemia and right heart failure that had been caused by ...

Patients with SSc vs controls showed a greater prevalence of WMH on brain MRIs, particularly in deep white matter regions.

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that causes the gradual loss of motor neurons in the brain and spinal cord, leading to muscle weakness, paralysis, and ...

As of June 30, 2025, the Company’s cash, cash equivalents and investments were $274.9 million. The Company expects that its cash, cash equivalents and investments, as of June 30, 2025, will fund its ...

Janet Pope, MD, MPH, discusses screening and diagnostic approaches for interstitial lung disease in patients with systemic ...